Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
Study Goal
The researchers aimed to investigate current treatment practices for anemia in CKD patients, including the use of Erythropoiesis-Stimulating Agents (ESAs), and explore potential alternatives like HIF-PHIs.
Results Summary
The study found that while ESAs are traditionally used for anemia in CKD, they are associated with adverse cardiovascular events and hypo-responsiveness, prompting the exploration of HIF-PHIs as alternatives. HIF-PHIs show promise in stimulating erythropoiesis and regulating iron metabolism.
Population
Patients with chronic kidney disease (CKD).
Effective Dosage
Not Assessed
Duration
Not Assessed
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
iron supplementation | decrease | anemia | patients with chronic kidney disease (CKD) | - | has traditionally included | #1 |
erythropoiesis-stimulating agents (ESAs) | decrease | anemia | patients with chronic kidney disease (CKD) | - | has traditionally included | #2 |
erythropoiesis-stimulating agents (ESAs) | increase | cardiovascular (CV) events | - | - | adverse | #3 |
erythropoiesis-stimulating agents (ESAs) | no change | anemia | - | - | hypo-responsiveness | #4 |
hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) | increase | erythropoiesis | - | - | stimulate | #5 |
hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) | neutral | iron metabolism | - | - | regulate | #6 |
To investigate current treatment practices for anemia in patients with chronic kidney disease (CKD), issues surrounding current treatment practices, and the hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) that are currently in clinical trials. Treatment of anemia in patients with CKD has traditionally included iron supplementation and erythropoiesis-stimulating agents (ESAs). However, due to adverse cardiovascular (CV) events and hypo-responsiveness to ESA therapy, new agents are currently in clinical trials to treat anemia in patients with CKD. The HIF-PHIs stimulate erythropoiesis and regulate iron metabolism and are attractive alternatives to iron supplementation and ESAs.